CND Life Sciences Secures $13.5M Series A Funding for Neurodiagnostic Innovations

CND Life Sciences Successfully Completes $13.5 Million Series A Funding Round

CND Life Sciences, Inc. (CND) has made headlines with its recent announcement of raising $13.5 million in its Series A equity financing, bolstered by a significant $8.6 million from its latest Series A3 offering. This strategic funding marks an essential step in CND's mission to revolutionize neurodiagnostics, especially for conditions related to synucleinopathies such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB).

The company’s flagship product, the Syn-One Test®, utilizes skin biopsy samples to detect and quantify abnormal forms of alpha-synuclein proteins—markers often associated with neurodegenerative diseases. Since its launch in late 2019, the Syn-One Test has facilitated diagnosis for over 35,000 patients and is employed by nearly 3,000 neurologists and clinicians across the U.S.

According to Richard J. Morello, CEO of CND, this funding is crucial for advancing their technology and aiding earlier diagnoses of neurodegenerative diseases. “This is a defining time for the neurodegeneration field,” said Morello, emphasizing the importance of precise diagnostics in improving treatment outcomes.

A pivotal study published in the Journal of the American Medical Association in 2024 demonstrated that Syn-One Test boasts an overall sensitivity of 95.5% in identifying abnormal synuclein levels in patients with various synuclein-associated diseases. This remarkable statistic underscores the test's clinical utility, which has been validated in an NIH-sponsored multi-center study.

Christopher Gibbons, CND's Chief Scientific Officer, points out that accurate disease diagnosis and assessments of progression are vital for enhancing treatment pathways. He stated, “Our proprietary technology supports more precise diagnoses and convenient measures of disease progression and severity in PD, DLB, and other synucleinopathies.”

The funding sources for this Series A3 round included both existing and new investors, such as Labcorp, a renowned leader in laboratory services. Megann Vaughn Watters, Labcorp's vice president of New Ventures and Strategic Alliances, expressed excitement for supporting CND's vision. She highlighted the strong adoption of the Syn-One Test in addressing neurodegenerative diseases, ultimately bridging care gaps for affected patients.

Operating from a CLIA-certified and CAP-accredited facility in Scottsdale, Arizona, CND Life Sciences is committed to pioneering diagnostic technologies. Their innovative Syn-One Test employs immunofluorescence techniques to visualize and quantify phosphorylated alpha-synuclein in small skin biopsy samples sourced through straightforward in-office procedures. The evaluation assesses intraepidermal nerve fiber density and other critical pathological markers.

The company is not merely focused on diagnostics; they also collaborate with biopharmaceutical firms for clinical trial advancements aimed at novel therapies targeting neurodegenerative diseases. As CND Life Sciences continues to focus on bridging extensive healthcare gaps, its recent funding round will undoubtedly bolster its efforts in finally providing patients and clinicians with the vital tools needed to combat neurodegenerative conditions.

For more on CND Life Sciences, including their continuing innovations and developments in neuroDiagnostics, visit cndlifesciences.com.